Ascendis Pharma A/S
Price Action
Technical Summary
STAGE 2 UPTRENDAscendis Pharma A/S is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is moderate (RS Rating: 73), indicating performance broadly in line with the market. Earnings growth of 16% provides fundamental context to the price action. Momentum will need to be maintained above the 50-day moving average to sustain this leadership phase.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $224.81 | +3.87% | ABOVE |
| 50 SMA | $218.92 | +6.66% | ABOVE |
| 100 SMA | $212.72 | +9.77% | ABOVE |
| 150 SMA | $206.18 | +13.25% | ABOVE |
| 200 SMA | $197.12 | +18.46% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is ASND in an uptrend right now?
ASND has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, ASND is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is ASND overbought or oversold?
ASND's RSI (14) is 55. The stock is in neutral territory, neither overbought nor oversold.
Is ASND outperforming the market?
ASND has a Relative Strength (RS) Rating of 73 out of 99. ASND is performing about average compared to the market.
Where is ASND in its 52-week range?
ASND is trading at $233.50, which is 96% of its 52-week high ($242.00) and 93% above its 52-week low ($124.06).
How volatile is ASND?
ASND has a Beta of 0.24 and 52-week volatility of 39%. It's less volatile than the S&P 500 - generally more stable.